Terms: = Ovarian cancer AND DROSHA, HSA242976, 29102, RNASEN, ENSG00000113360, Q9NRR4, RNASE3L, RN3, RANSE3L, Etohi2
21 results:
1. Ascitic fluid shear stress in concert with hepatocyte growth factor drive stemness and chemoresistance of ovarian cancer cells via the c-Met-PI3K/Akt-miR-199a-3p signaling pathway.
Hassan AA; Artemenko M; Tang MKS; Shi Z; Chen LY; Lai HC; Yang Z; Shum HC; Wong AST
Cell Death Dis; 2022 Jun; 13(6):537. PubMed ID: 35676254
[TBL] [Abstract] [Full Text] [Related]
2. Integrated Analysis of ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements.
Vougiouklakis T; Zhu K; Vasudevaraja V; Serrano J; Shen G; Linn RL; Feng X; Chiang S; Barroeta JE; Thomas KM; Schwartz LE; Shukla PS; Malpica A; Oliva E; Cotzia P; DeLair DF; Snuderl M; Jour G
Clin Cancer Res; 2022 Apr; 28(8):1724-1733. PubMed ID: 35031544
[TBL] [Abstract] [Full Text] [Related]
3. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer.
Khan S; Ayub H; Khan T; Wahid F
Biochimie; 2019 Dec; 167():12-24. PubMed ID: 31493469
[TBL] [Abstract] [Full Text] [Related]
5. Role of components of microRNA machinery in carcinogenesis.
Kian R; Moradi S; Ghorbian S
Exp Oncol; 2018 Mar; 40(1):2-9. PubMed ID: 29600985
[TBL] [Abstract] [Full Text] [Related]
6. The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
Wang X; Ivan M; Hawkins SM
Gynecol Oncol; 2017 Nov; 147(2):481-487. PubMed ID: 28866430
[TBL] [Abstract] [Full Text] [Related]
7. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.
Rupaimoole R; Ivan C; Yang D; Gharpure KM; Wu SY; Pecot CV; Previs RA; Nagaraja AS; Armaiz-Pena GN; McGuire M; Pradeep S; Mangala LS; Rodriguez-Aguayo C; Huang L; Bar-Eli M; Zhang W; Lopez-Berestein G; Calin GA; Sood AK
Oncogene; 2016 Aug; 35(33):4312-20. PubMed ID: 26725326
[TBL] [Abstract] [Full Text] [Related]
8. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and drosha expression].
Yang Y; Han K; Xie Y
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA related polymorphisms and breast cancer risk.
Khan S; Greco D; Michailidou K; Milne RL; Muranen TA; Heikkinen T; Aaltonen K; Dennis J; Bolla MK; Liu J; Hall P; Irwanto A; Humphreys K; Li J; Czene K; Chang-Claude J; Hein R; Rudolph A; Seibold P; Flesch-Janys D; Fletcher O; Peto J; dos Santos Silva I; Johnson N; Gibson L; Aitken Z; Hopper JL; Tsimiklis H; Bui M; Makalic E; Schmidt DF; Southey MC; Apicella C; Stone J; Waisfisz Q; Meijers-Heijboer H; Adank MA; van der Luijt RB; Meindl A; Schmutzler RK; Müller-Myhsok B; Lichtner P; Turnbull C; Rahman N; Chanock SJ; Hunter DJ; Cox A; Cross SS; Reed MW; Schmidt MK; Broeks A; Van't Veer LJ; Hogervorst FB; Fasching PA; Schrauder MG; Ekici AB; Beckmann MW; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Benitez J; Zamora PM; Perez JI; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Pharoah PD; Dunning AM; Shah M; Luben R; Brown J; Couch FJ; Wang X; Vachon C; Olson JE; Lambrechts D; Moisse M; Paridaens R; Christiaens MR; Guénel P; Truong T; Laurent-Puig P; Mulot C; Marme F; Burwinkel B; Schneeweiss A; Sohn C; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Andrulis IL; Knight JA; Tchatchou S; Mulligan AM; Dörk T; Bogdanova NV; Antonenkova NN; Anton-Culver H; Darabi H; Eriksson M; Garcia-Closas M; Figueroa J; Lissowska J; Brinton L; Devilee P; Tollenaar RA; Seynaeve C; van Asperen CJ; Kristensen VN; ; ; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Lindblom A; Margolin S; Radice P; Peterlongo P; Barile M; Mariani P; Hooning MJ; Martens JW; Collée JM; Jager A; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Giles GG; McLean C; Brauch H; Brüning T; Ko YD; ; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Swerdlow A; Ashworth A; Orr N; Jones M; Simard J; Goldberg MS; Labrèche F; Dumont M; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Kataja V; Kosma VM; Hartikainen JM; Mannermaa A; Hamann U; Chenevix-Trench G; Blomqvist C; Aittomäki K; Easton DF; Nevanlinna H
PLoS One; 2014; 9(11):e109973. PubMed ID: 25390939
[TBL] [Abstract] [Full Text] [Related]
10. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.
Han C; Liu Y; Wan G; Choi HJ; Zhao L; Ivan C; He X; Sood AK; Zhang X; Lu X
Cell Rep; 2014 Sep; 8(5):1447-60. PubMed ID: 25176654
[TBL] [Abstract] [Full Text] [Related]
11. Application of microRNA in diagnosis and treatment of ovarian cancer.
Banno K; Yanokura M; Iida M; Adachi M; Nakamura K; Nogami Y; Umene K; Masuda K; Kisu I; Nomura H; Kataoka F; Tominaga E; Aoki D
Biomed Res Int; 2014; 2014():232817. PubMed ID: 24822185
[TBL] [Abstract] [Full Text] [Related]
12. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
[TBL] [Abstract] [Full Text] [Related]
13. Argonaute, Dicer, and drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract] [Full Text] [Related]
14. MicroRNA processing and binding site polymorphisms are not replicated in the ovarian cancer Association Consortium.
Permuth-Wey J; Chen Z; Tsai YY; Lin HY; Chen YA; Barnholtz-Sloan J; Birrer MJ; Chanock SJ; Cramer DW; Cunningham JM; Fenstermacher D; Fridley BL; Garcia-Closas M; Gayther SA; Gentry-Maharaj A; Gonzalez-Bosquet J; Iversen E; Jim H; McLaughlin J; Menon U; Narod SA; Phelan CM; Ramus SJ; Risch H; Song H; Sutphen R; Terry KL; Tyrer J; Vierkant RA; Wentzensen N; Lancaster JM; Cheng JQ; Berchuck A; Pharoah PD; Schildkraut JM; Goode EL; Sellers TA;
Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1793-7. PubMed ID: 21636674
[TBL] [Abstract] [Full Text] [Related]
15. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DD
PLoS One; 2011 Apr; 6(4):e18064. PubMed ID: 21533284
[TBL] [Abstract] [Full Text] [Related]
16. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.
Permuth-Wey J; Kim D; Tsai YY; Lin HY; Chen YA; Barnholtz-Sloan J; Birrer MJ; Bloom G; Chanock SJ; Chen Z; Cramer DW; Cunningham JM; Dagne G; Ebbert-Syfrett J; Fenstermacher D; Fridley BL; Garcia-Closas M; Gayther SA; Ge W; Gentry-Maharaj A; Gonzalez-Bosquet J; Goode EL; Iversen E; Jim H; Kong W; McLaughlin J; Menon U; Monteiro AN; Narod SA; Pharoah PD; Phelan CM; Qu X; Ramus SJ; Risch H; Schildkraut JM; Song H; Stockwell H; Sutphen R; Terry KL; Tyrer J; Vierkant RA; Wentzensen N; Lancaster JM; Cheng JQ; Sellers TA;
Cancer Res; 2011 Jun; 71(11):3896-903. PubMed ID: 21482675
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of novel microRNAs in female reproductive tract using next generation sequencing.
Creighton CJ; Benham AL; Zhu H; Khan MF; Reid JG; Nagaraja AK; Fountain MD; Dziadek O; Han D; Ma L; Kim J; Hawkins SM; Anderson ML; Matzuk MM; Gunaratne PH
PLoS One; 2010 Mar; 5(3):e9637. PubMed ID: 20224791
[TBL] [Abstract] [Full Text] [Related]
18. The dicey role of Dicer: implications for RNAi therapy.
Merritt WM; Bar-Eli M; Sood AK
Cancer Res; 2010 Apr; 70(7):2571-4. PubMed ID: 20179193
[TBL] [Abstract] [Full Text] [Related]
19. Dicer, drosha, and outcomes in patients with ovarian cancer.
Merritt WM; Lin YG; Han LY; Kamat AA; Spannuth WA; Schmandt R; Urbauer D; Pennacchio LA; Cheng JF; Nick AM; Deavers MT; Mourad-Zeidan A; Wang H; Mueller P; Lenburg ME; Gray JW; Mok S; Birrer MJ; Lopez-Berestein G; Coleman RL; Bar-Eli M; Sood AK
N Engl J Med; 2008 Dec; 359(25):2641-50. PubMed ID: 19092150
[TBL] [Abstract] [Full Text] [Related]
20. Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Laios A; O'Toole S; Flavin R; Martin C; Kelly L; Ring M; Finn SP; Barrett C; Loda M; Gleeson N; D'Arcy T; McGuinness E; Sheils O; Sheppard B; O' Leary J
Mol Cancer; 2008 Apr; 7():35. PubMed ID: 18442408
[TBL] [Abstract] [Full Text] [Related]
[Next]
